Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Candel Therapeutics Inc (CADL)

Candel Therapeutics Inc (CADL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Wed Jul 1, 3:05PM CDT

NEEDHAM, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies...

CADL : 9.83 (-0.51%)
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors GlobeNewswire - Tue Jun 30, 7:05AM CDT

Phase 3 clinical trial will evaluate aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab versus standard-of-care docetaxel chemotherapy in patients with metastatic, non-squamous,...

CADL : 9.83 (-0.51%)
Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer GlobeNewswire - Thu Jun 25, 7:05AM CDT

Appointment supports planned Biologics License Application (BLA) submission in the fourth quarter of 2026 and potential 2027 launch of aglatimagene besadenovec in localized prostate cancer NEEDHAM,...

CADL : 9.83 (-0.51%)
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer GlobeNewswire - Tue Jun 2, 7:05AM CDT

Peer reviewed publication details pivotal data, demonstrating 30% improvement in disease-free survival (DFS) in patients with localized prostate cancer undergoing standard-of-care radiotherapy with curative...

CADL : 9.83 (-0.51%)
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon Jun 1, 3:05PM CDT

NEEDHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies...

CADL : 9.83 (-0.51%)
MarketBeat.com
Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data MarketBeat - Wed May 20, 10:13AM CDT

Candel Therapeutics (NASDAQ:CADL) Chief Executive Officer Dr. Paul Peter Tak said the company remains focused on advancing its viral immunotherapy programs following newly presented prostate cancer data...

CADL : 9.83 (-0.51%)
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting GlobeNewswire - Fri May 15, 3:05PM CDT

Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed a statistically significant and clinically meaningful improvement in prostate...

CADL : 9.83 (-0.51%)
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights GlobeNewswire - Thu May 14, 7:05AM CDT

Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- to high-risk prostate cancer in Q4 2026 Announced purpose-built...

CADL : 9.83 (-0.51%)
Candel Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire - Wed May 13, 7:05AM CDT

NEEDHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) --  Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies...

CADL : 9.83 (-0.51%)
Candel Therapeutics Reports Before Its Prostate Cancer Data Reveal—Or Is That the Other Way Around Barchart - Mon May 11, 4:02PM CDT

Barchart Research What to Expect from CADL Earnings CADL Generated May 11, 2026 Current Price $8.85 EPS Estimate $$-0.22 Consensus Rating Moderate Buy Average Move 8.92% Candel Therapeutics Reports Before...

CADL : 9.83 (-0.51%)

Barchart Exclusives

The Microsoft Stock Outlook Remains Upbeat Despite Layoffs Barchart - Sun Jul 5, 5:14PM CDT
Microsoft has become a big beneficiary of the AI boom. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.